Science Park, 14 Einstein Street
P.O. Box 4143
162 articles with BiondVax Pharmaceuticals
BiondVax Pharmaceuticals Ltd. today announced its financial results for the quarter ended September 30, 2018.
BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants
Phase 3 trial of the M-001 universal flu vaccine candidate.
BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of an €8 million disbursement from the European Investment Bank (EIB).
BiondVax Pharmaceuticals Ltd. reported today it will present at the Influenza 2018 Oxford conference at the University of Oxford.
BiondVax Pharmaceuticals Ltd. announced its financial results for the quarter ended June 30, 2018.
State-of-the-art facility designed for annual capacity of 40 million doses in bulk with up to 20 million single dose syringes
BiondVax Pharmaceuticals Ltd. announced today the receipt of a €6 million disbursement from the European Investment Bank (EIB).
BiondVax Pharmaceuticals Ltd. reported today the first participant's initial visit in a pivotal clinical efficacy Phase 3 trial of the M-001 universal flu vaccine candidate.
BiondVax Pharmaceuticals Ltd. announced the receipt of a €6 million disbursement from the European Investment Bank (EIB).
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
BiondVax Pharmaceuticals Ltd. announced its fourth quarter and full year financial results for the year ended December 31, 2017 and provided a business update.
BiondVax Pharmaceuticals Ltd. reported today it will present at the Universal Influenza Vaccines 2018 Conference.
BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States
The trial is sponsored by the US National Institute of Allergy and Infectious Disease.
BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement (MSA) with a contract research organization (CRO) to conduct the first pivotal, clinical efficacy, Phase 3 trial of M-001.
The patent belongs to BiondVax's portfolio family titled "Multimeric Multi-Epitope Influenza Vaccines" and has now been granted in over 30 countries.
BiondVax announced today that the EMA's CHMP reviewed BiondVax's Phase 3 trial plan, provided advice, and allowed the Company to proceed with the Phase 3 clinical trial plan for M-001, BiondVax's universal flu vaccine candidate.
BiondVax today released a Letter from the CEO regarding recent activities and plans.
BiondVax today announced its financial results for the quarter ended September 30, 2017 and provided a business update.
BiondVax and NIH Sign Clinical Trial Agreement for a Phase II Trial in the U.S. with BiondVax's Universal Flu Vaccine
The study designed to evaluate the cell mediated immunity directly induced by BiondVax's universal flu vaccine candidate M-001, as well as M-001's priming effect to enhance the immunogenicity of current seasonal influenza vaccines.
BiondVax Announces Closing Of $10 Million Public Offering Of American Depositary Shares And Exercise Of Over-Allotment Option